Retatrutide + Cagrilintide
A research pairing of two weight-loss peptides that work on different pathways.
Also listed as Reta/Cagri, Retatrutide/Cagrilintide.
Peptide Compare tracked 2 vendors selling Retatrutide + Cagrilintide on 8 Oct 2026. The cheapest in-stock 10 mg vial is $8.80 per mg at Good Science after its 20% coupon, 18% under the $10.78 median. Prices are scraped from vendor sites; trust scores come from Finnrick blind tests.
Some outbound links may earn us a commission. Vendors cannot pay to improve rankings.
Best value right now · all sizes
GS
Good Science
IN STOCKUNTESTED
Per mg18% under the $10.78 median
Vial price10 mg · verified Oct 8
Compare 2 vendors
Across all sizes, verified in-stock listings run $110.00 to $150.00 from 2 vendors.
VendorSizeStock
Retatrutide + Cagrilintide prices verified Oct 8, 2026
$8.80/mgGood Science · $88.00
Buy best priceSee how Retatrutide + Cagrilintide moved against the rest of the catalogue in the Peptide Price Index: median price per mg now versus 30 and 90 days ago, every tracked peptide, with a CSV.
Retatrutide + Cagrilintide price by vial size
| Vial size | Lowest per mg | Vial price | Vendor |
|---|---|---|---|
| 10 mg | $8.80 | $88.00 | Good Science2 vendors carry it |
Verified 8 Oct 2026. Lowest figures are in-stock listings checked within the last week, with any coupon applied; a size with none says so.
Price movement · 30 days
0%median per mg, all sizes
Cheapest ever recorded: $11.00/mg on Aug 16. Today matches it.See our top-ranked Retatrutide + Cagrilintide vendors
Ranked by Finnrick trust score, independent lab testing, and price.
Quick Summary
A pairing of retatrutide and cagrilintide, neither of which is approved anywhere. No trial has tested them together. Available from 2 vendors, priced from $110.00 to $150.00.
Research: A ClinicalTrials.gov search for both agents together returns zero studies. The individual figures are real: retatrutide reached a 24.2% mean weight change at 48 weeks on 12 mg against 2.1% on placebo in its Phase 2 (Jastreboff et al, NEJM 2023, PMID 37366315), and CagriSema reached 20.4% at 68 weeks in REDEFINE-1. Neither result says anything about what the two do together.
Side effects: No adverse event data exists for the combination
Research compoundNo trial of the combination; neither component is approved
- 2 of 2 vendors currently have it in stock
- Most common vial size: 10mg
- Category: Weight Loss (GLP-1) — GLP-1 receptor agonists for weight management
Get Retatrutide + Cagrilintide price alerts
Join the list — price-drop alerts for this peptide are in the works and you'll be first on them.